Fig. 1From: Circulating tumor cells as marker of poor prognosis in metastatic lung cancer: a pilot studyProgression Free-Survival of patients with lung cancer that evaluated CTM before systemic treatment (With CTM, dotted line: median PFS of 3.1 months vs. Without CTM, continuous line: 6.7 months; p = 0.29)Back to article page